Background illustration for clinical trials search

Vaccines Clinical Trials

Find clinical trials for vaccines. Search for vaccines clinical trials in different cities and states across the United States.

Filter

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

for
Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT06439693

Phase 2, Recruiting

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for
Cardiotoxicity, HER2/Neu Positive,
Location: Winchester MA, Burlington MA, White Plains NY, Nyack NY,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT03418961

Phase 3, Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, HR+/HER2- Breast Cancer,
Location: Mineola NY, New York NY, Sarasota FL, Portland OR,
Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05867251

Phase 1, Phase 2, Recruiting

The Minimalist Trial-2

for
HPV-Related Oropharynx Squamous Cell Carcinoma
Location: St Louis MO, Fargo ND, Sioux Falls SD
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06702033

Phase 2, Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

for
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: The Bronx NY, Newark NJ, New Brunswick NJ, Baltimore MD,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05172245

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for
Breast Cancer, Gastric Cancer, Esophageal Cancer,
Location: Lake Success NY, New York NY, Nashville TN, Westwood KS,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06695845

Phase 2, Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC),
Location: Boston MA, New York NY, Sarasota FL, Columbus OH,
Sponsor: Olema Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06784193

Phase 1, Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Gloucester MA, Beverly MA, Peabody MA, Burlington MA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06058377

Phase 3, Recruiting

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

for
Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
Location: New Haven CT
Sponsor: Yale University

Sex: Female

Age: 18+

Code: NCT05989347

Phase 1, Recruiting

Optimizing Influenza Vaccination in Surgical Oncology Patients

for
Influenza
Location: Stony Brook NY
Sponsor: Stony Brook University

Sex: All

Age: 18+

Code: NCT01698177

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

for
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Location: Montreal, Fort Lauderdale FL, Toronto, Pittsburgh PA,
Sponsor: Bayer

Sex: All

Age: 18+

Code: NCT06452277

Phase 3, Recruiting

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

for
HER2-positive Breast Cancer
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: Female

Age: 18+

Code: NCT04332588

Phase 1, Recruiting

Sacituzumab Govitecan In TNBC

for
Invasive Breast Cancer, Triple Negative Breast Cancer,
Location: Danvers MA, Boston MA, Newton MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT04230109

Phase 2, Recruiting

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

for
Breast Cancer, PALB2-Mutated Breast Carcinoma,
Location: Boston MA, Rochester MN
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT06488378

Phase 1, Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for
Breast Cancer, HER2-positive Breast Cancer
Location: Brewer ME, Scarborough ME, Weymouth MA, Danvers MA,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04893109

Phase 2, Recruiting

A Phase 1/2 Study of IAM1363 in HER2 Cancers

for
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer,
Location: Boston MA, Lebanon NH, New York NY, New Brunswick NJ,
Sponsor: Iambic Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT06253871

Phase 1, Phase 2, Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

for
Respiratory Tract Diseases, Influenza (Pandemic), Influenza,
Location: Quebec, Sherbrooke, New York NY, Montreal, Ottawa,
Sponsor: UMC Utrecht

Sex: All

Age: 0+

Code: NCT02735707

Phase 3, Recruiting

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

for
HER2-positive Breast Cancer, Advanced Breast Cancer
Location: Boston MA, Miami FL
Sponsor: University of Miami

Sex: Female

Age: 18+

Code: NCT06123988

Recruiting

The Effects of Endotracheal Suctioning on Pain and Serum Markers

for
Intensive Care Unit ICU, Intubation, Critical Illness,
Location: Loma Linda CA
Sponsor: Loma Linda University

Sex: All

Age: 18+

Code: NCT06692400

Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for
Carcinoma, Non-Small Cell Lung,
Location: Boston MA, Newton MA, Shirley NY, Riverhead NY,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT04389632

Phase 1, Recruiting

What vaccine clinical trials are studying now

New flu vaccines. Moderna's mFlusiva, approved August 5, 2026 for adults 50 and older, is the first mRNA flu vaccine. In its Phase 3 trial it prevented about 27 percent more flu cases than a standard dose vaccine, with more short term side effects. Flu vaccine studies, including human challenge trials, are listed on our influenza clinical trials page.

Vaccines in pregnancy. Vaccinating a mother so antibodies pass to the baby is one of the most active areas of research. A Phase 3 trial of a group B streptococcus vaccine, a leading cause of serious infection in newborns, is recruiting pregnant participants at 120 US sites.

Pneumococcal and other bacterial vaccines. Next generation vaccines that cover more strains of the bacteria behind pneumonia and meningitis, tested against the vaccines in use today. Two pneumococcal vaccine studies are enrolling healthy adults 18 to 75 who have never had a pneumococcal vaccine.

RSV vaccines. Combination and revaccination studies, covered on our RSV vaccine clinical trials page. Studies of new flu and RSV vaccines for adults 60 and older are enrolling now.

Cancer vaccines. These do not prevent cancer; they teach the immune system to attack a cancer that is already there. Intismeran, made for each patient from up to 34 mutations in their own tumor, met its main goal in a Phase 3 melanoma trial in August 2026 but is not yet approved. Smaller studies test vaccines for HER2 positive breast cancer, liver cancer, and HPV related cancers; see our melanoma and breast cancer pages.

COVID-19. Updated formulas are approved each season; the 2026 to 2027 mRNA formula is approved for adults 65 and older and for people 5 to 64 with a condition that raises their risk. One study is testing a COVID-19 vaccine given during an active infection, for people 12 and older who tested positive within the past 5 days and have a risk factor for severe illness; it measures the immune response and is not a treatment for the current illness. Studies of COVID-19 and long COVID are on our COVID-19 page.

Vaccines for infections that have none yet. There is still no approved vaccine against Epstein-Barr virus, the cause of mono, or against C. difficile, a common hospital infection. A study of an EBV vaccine is enrolling healthy adults 18 to 30, and C. diff vaccine studies are enrolling adults 65 and older who have frequent contact with healthcare but have never had the infection.

Human challenge studies. Healthy adults receive a vaccine or placebo, then a controlled dose of a virus such as influenza, in a monitored setting. They answer in weeks what field trials take seasons to show.

Article preview image

65 or older? Read our guide: Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

How vaccine trials differ from drug trials

Who can participate in vaccine clinical trials?

Do vaccine trial participants get paid?

How to enroll in a vaccine clinical trial